Skip to main content


COVID-19 drug price deemed 'reasonable'

   June 30, 2020

Gilead Sciences announced pricing for the first drug authorized to treat COVID-19 in the United States, and industry observers did not immediately pass out from sticker shock. The price range for the drug remdesivir — $3,120 for commercially insured U.S. patients, and $2,340 for government programs here and abroad — was in the neighborhood of the pricing suggestions announced previously by the independent Institute for Clinical and Economic Review (ICER) in Boston.

Full story

Get the latest on healthcare leadership in your inbox.